An ongoing dialogue on HIV/AIDS, infectious diseases,
September 7th, 2015
Two Drugs with High Prices — One is (Surprise!) Good Value, The Other is Truly a Rip-off
By now, the fact that HCV treatment carries a high price is a fact as well known to the medical and non-medical public as 1) a million dollars doesn’t get you much in Manhattan or Bay-area real estate; 2) a Rolex is an expensive way to know what time it is; and 3) even though […]
Paul E. Sax, MD
Contributing Editor
NEJM Journal Watch
Infectious Diseases
Biography | Disclosures | Summaries
Learn more about HIV and ID Observations.
NEJM Journal Watch — Recent Infectious Disease Articles- When it Comes to Antimicrobial Stewardship, Is a Boost Better Than a Nudge?
- HIV Prevention and Treatment: Updated Recommendations from the International AIDS Society–USA
- Observations from ID and Beyond: Dr. Thomas O'Brien — Expert in Antimicrobial Resistance and Giant in His Field (Literally)
- How Serious Is Artemisinin Partial Resistance in African Malaria Parasites?
- Observations from ID and Beyond: Who's Going to Get Lenacapavir for HIV Prevention?